{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:54:14Z","timestamp":1790268854979,"version":"4.1.0"},"reference-count":83,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:00:00Z","timestamp":1717891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Therapeutic advances in oncology in the 21st century have contributed to significant declines in cancer mortality. Notably, targeted therapies comprised the largest proportion of oncology drugs approved by the United States (US) Food and Drug Administration (FDA) over the past 25 years and have become the standard of care for the treatment of many cancers. However, despite the metamorphosis of the therapeutic landscape, some aspects of cancer drug development have remained essentially unchanged. In particular, the dose-finding methodology originally developed for cytotoxic chemotherapy drugs continues to be implemented, even though this approach no longer represents the most appropriate strategy for modern cancer therapies. In recognition of the need to reconsider assumptions, adapt the dose selection process for newer drugs, and design alternative strategies, the FDA has undertaken several initiatives in recent years to address these concerns. These actions include the launch of Project Optimus in 2021 and the issuance of draft guidance for industry on dose optimization of oncology drugs in 2023. Amid this evolving regulatory environment, the present manuscript reviews case studies for six different targeted cancer therapies, highlighting how dose-finding challenges have been managed to date by oncologists, sponsors, and regulators.<\/jats:p>","DOI":"10.3390\/cancers16122180","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T08:59:06Z","timestamp":1718009946000},"page":"2180","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dose Optimization of Targeted Therapies for Oncologic Indications"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-0066","authenticated-orcid":false,"given":"Marjorie E.","family":"Zettler","sequence":"first","affiliation":[{"name":"Clinical Science, Accutar Biotechnology Inc., Cranbury, NJ 08512, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_3","unstructured":"Food and Drug Administration (2024, April 27). Project Optimus, Available online: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus."},{"key":"ref_4","unstructured":"Food and Drug Administration (2024, April 27). Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases. Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/164555\/download."},{"key":"ref_5","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2024, April 27). ICH-E4 Guideline for Industry: Dose-Response Information to Support Drug Registration, Available online: https:\/\/www.fda.gov\/media\/71279\/download."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-022-04444-0","article-title":"Oncology dose optimization paradigms: Knowledge gained and extrapolated from approved oncology therapeutics","volume":"90","author":"Mittapalli","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Loeser, A., Kim, J.S., Peppercorn, J., Burkard, M.E., Niemierko, A., Juric, D., Kalinsky, K., Rugo, H., Glenn, L., and Hodgdon, C. (2024). The Right Dose: Results of a Patient Advocate-Led Survey of Individuals with Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncol. Pract., OP2300539. Available online: https:\/\/ascopubs.org\/doi\/10.1200\/OP.23.00539.","DOI":"10.1200\/OP.23.00539"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10549-022-06755-5","article-title":"Patient-centered dosing: Oncologists\u2019 perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC)","volume":"196","author":"Loeser","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_9","unstructured":"Food and Drug Administration (2024, April 27). Approval Letter for Ibrutinib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/205552Orig2s000ltr.pdf."},{"key":"ref_10","unstructured":"Food and Drug Administration (2024, April 27). Prescribing Information for Ibrutinib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205552Orig2lbl.pdf."},{"key":"ref_11","unstructured":"Food and Drug Administration (2024, April 27). Medical Review Package for Ibrutinib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205552Orig2s000MedR.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2018-06-860593","article-title":"A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1807","DOI":"10.1200\/OP.22.00427","article-title":"Oncologists\u2019 Perspectives on Individualizing Dose Selection for Patients with Metastatic Cancer","volume":"18","author":"Jimenez","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_17","unstructured":"Food and Drug Administration (2024, April 27). Approval Letter for Pazopanib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2009\/022465s000ltr.pdf."},{"key":"ref_18","unstructured":"Food and Drug Administration (2024, April 27). Prescribing Information for Pazopanib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022465lbl.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_21","unstructured":"Food and Drug Administration (2024, April 27). Medical Review Package for Pazopanib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022465s000_MedR.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cpt.1515","article-title":"The Effect of Using Pazopanib with Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study)","volume":"106","author":"Lubberman","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_23","unstructured":"Food and Drug Administration (2024, April 27). Approval Letter for Regorafenib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2012\/203085Orig1s000ltr.pdf."},{"key":"ref_24","unstructured":"Food and Drug Administration (2024, April 27). Prescribing Information for Regorafenib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203085lbl.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","article-title":"A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors","volume":"8","author":"Mross","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"ref_27","unstructured":"Food and Drug Administration (2024, April 27). Medical Review Package for Regorafenib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203085Orig1s000MedR.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): A randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Ou","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_29","unstructured":"National Comprehensive Cancer Network (2024, April 27). NCCN Guidelines Version 4.2023 Colon Cancer. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.1016\/j.annonc.2022.04.192","article-title":"Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: A retrospective analysis using US claims data","volume":"33","author":"Khan","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_31","unstructured":"Food and Drug Administration (2024, April 27). Approval Letter for Niraparib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/208447Orig1s000Ltr.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_33","unstructured":"Food and Drug Administration (2024, April 27). Prescribing Information for Niraparib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208447lbl.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_35","unstructured":"Food and Drug Administration (2024, April 27). Multi-Discipline Review Package for Niraparib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208447Orig1s000MultidisciplineR.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_37","unstructured":"Food and Drug Administration (2024, April 27). Prescribing Information for Niraparib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208447s015s017lbledt.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2023.41.16_suppl.1598","article-title":"Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks","volume":"41","author":"Heiss","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/1078-0432.CCR-23-2268","article-title":"An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the U.S. Food and Drug Administration, 2012\u20132022","volume":"30","author":"Collins","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_40","unstructured":"Food and Drug Administration (2024, April 27). Approval Letter for Futibatinib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/214801Orig1s000Correctedltr.pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_43","unstructured":"Food and Drug Administration (2024, April 27). Prescribing Information for Futibatinib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214801Orig1s000lbledt.pdf."},{"key":"ref_44","unstructured":"Food and Drug Administration (2024, April 27). Multi-Discipline Review Package for Futibatinib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214801Orig1s000MultidisciplineR.pdf."},{"key":"ref_45","unstructured":"Food and Drug Administration (2024, April 27). Approval Letter for Melphalan Flufenamide, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/214383Orig1s000ltr.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): A multicentre, international, open-label, phase 1-2 study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_48","unstructured":"Food and Drug Administration (2024, April 27). Prescribing Information for Melphalan Flufenamide, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214383s000lbl.pdf."},{"key":"ref_49","unstructured":"Food and Drug Administration and Oncopeptides (2024, April 27). Combined FDA and Applicant Oncologic Drugs Advisory Committee Briefing Document, Available online: https:\/\/www.fda.gov\/media\/161678\/download."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","article-title":"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): A randomised, head-to-head, open-label, phase 3 study","volume":"9","author":"Schjesvold","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_51","unstructured":"Oncopeptides (2024, April 27). Press Release: Oncopeptides Withdraws Pepaxto\u00ae in US, Scale down Organization and Focus on R&D. Available online: https:\/\/oncopeptides.com\/en\/media\/press-releases\/oncopeptides-withdraws-pepaxto-in-us-scale-down-organization-and-focus-on-rd."},{"key":"ref_52","unstructured":"Oncopeptides (2024, April 27). Press Release: Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US\u2014No Intent to Market in the US at This Time. Available online: https:\/\/oncopeptides.com\/en\/media\/press-releases\/oncopeptides-rescinds-voluntary-withdrawal-of-pepaxto-in-the-us-no-intent-to-market-in-the-us-at-this-time\/."},{"key":"ref_53","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research (2024, April 27). Final Summary Minutes of the Oncologic Drugs Advisory Committee Meeting September 22\u201323 2022, Available online: https:\/\/www.fda.gov\/media\/164048\/download."},{"key":"ref_54","unstructured":"Food and Drug Administration (2024, April 27). Notice of Proposed Withdrawal of Approval; PEPAXTO (Melphalan Flufenamide) for Injection; NDA 214383, Available online: https:\/\/downloads.regulations.gov\/FDA-2023-N-3167-0002\/attachment_1.pdf."},{"key":"ref_55","unstructured":"Food and Drug Administration (2024, April 27). FDA Issues Final Decision to Withdraw Approval of Pepaxto (Melphalan Flufenamide), Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-issues-final-decision-withdraw-approval-pepaxto-melphalan-flufenamide."},{"key":"ref_56","unstructured":"BIO (2024, April 27). Clinical Development Success Rates and Contributing Factors 2011\u20132020. Available online: https:\/\/go.bio.org\/rs\/490-EHZ-999\/images\/ClinicalDevelopmentSuccessRates2011_2020.pdf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"ref_58","unstructured":"Tracey, A. (2022). Pazdur at FDA-ASCO workshop: Failure to optimize the dose is akin to building a house on quicksand. Cancer Lett., 48, Available online: https:\/\/cancerletter.com\/regulatory-news\/20220506_8\/."},{"key":"ref_59","unstructured":"Food and Drug Administration (2024, April 27). Expedited Programs for Serious Conditions\u2014Drugs and Biologics. Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/86377\/download."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The Drug-Dosing Conundrum in Oncology\u2014When Less Is More","volume":"385","author":"Shah","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1200\/JCO.22.00371","article-title":"Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients","volume":"40","author":"Shah","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_63","first-page":"PO.21.00136","article-title":"Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials","volume":"5","author":"Silva","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ejca.2014.04.031","article-title":"Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study","volume":"50","author":"Collette","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00280-020-04202-0","article-title":"Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: Learnings from a survey of FDA-approved drugs","volume":"87","author":"Mittapalli","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/psp4.13033","article-title":"US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer","volume":"12","author":"Shord","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"17407745231207085","DOI":"10.1177\/17407745231207085","article-title":"Statistical and practical considerations in planning and conduct of dose-optimization trials","volume":"21","author":"Yuan","year":"2024","journal-title":"Clin. Trials"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1186\/s13063-023-07793-0","article-title":"A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials","volume":"24","author":"Lee","year":"2023","journal-title":"Trials"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Yang, P., Li, D., Lin, R., Huang, B., and Yuan, Y. (2023). Design and Sample Size Determination for Multiple-dose Randomized Phase II Trials for Dose Optimization. arXiv.","DOI":"10.1002\/sim.10093"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/biom.13840","article-title":"DROID: Dose-ranging approach to optimizing dose in oncology drug development","volume":"79","author":"Guo","year":"2023","journal-title":"Biometrics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102238","DOI":"10.1016\/j.eclinm.2023.102238","article-title":"Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): A multi-center, single-arm, phase 2 trial","volume":"64","author":"Liu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(17)30378-8","article-title":"Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): A phase 1, open-label, dose-escalation and dose-expansion study","volume":"5","author":"Ahn","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_73","unstructured":"AstraZeneca (2024, April 27). Protocol: A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients with EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC). Available online: http:\/\/filehosting.pharmacm.com\/DownloadService.ashx?client=CTR_MED_7111&studyid=2978&filename=BLOOM%20CSP_Redacted%20new.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin. Trials"},{"key":"ref_75","unstructured":"Alpha Biopharma (2024, April 27). Press Release: Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-Mutated NSCLC Patients with CNS Metastases. Available online: https:\/\/www.prnewswire.com\/news-releases\/alpha-biopharma-submits-new-drug-application-for-zorifertinib-a-next-generation-egfr-tki-to-treat-egfr-mutated-nsclc-patients-with-cns-metastases-301733086.html."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.1200\/JCO.2023.41.16_suppl.9001","article-title":"Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non\u2013small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis","volume":"41","author":"Wu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_77","unstructured":"Food and Drug Administration (2024, April 27). Exposure-Response Relationships\u2014Study Design, Data Analysis, and Regulatory Applications. Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/71277\/download."},{"key":"ref_78","unstructured":"Food and Drug Administration (2024, April 27). Prescribing Information for Dasatinib, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021986s027lbl.pdf."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/bcp.13327","article-title":"Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib","volume":"83","author":"Lankheet","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/cts.12726","article-title":"Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy","volume":"13","author":"Reyner","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_81","first-page":"17407745241232428","article-title":"The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing-Challenging the \u201cmore is better\u201d dogma","volume":"21","author":"Loeser","year":"2024","journal-title":"Clin. Trials"},{"key":"ref_82","unstructured":"Food and Drug Administration (2024, April 27). OCE-Funded Active Extramural Research Projects, Available online: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/oce-funded-active-extramural-research-projects."},{"key":"ref_83","unstructured":"American Society of Clinical Oncology (2024, April 27). Press Release: ASCO Awarded $11M to Study Oral Drug Dosing Strategies in Older Adults with Metastatic Breast Cancer Receiving CDK4\/6 Inhibitors. Available online: https:\/\/society.asco.org\/about-asco\/press-center\/news-releases\/asco-awarded-11m-study-oral-drug-dosing-strategies-older."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/12\/2180\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:56:12Z","timestamp":1760108172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/12\/2180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,9]]},"references-count":83,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16122180"],"URL":"https:\/\/doi.org\/10.3390\/cancers16122180","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,9]]}}}